Physician profile
Lionel Handler
NPI 1013988260
$13,509.80
in general payments reported to CMS, 2019-2025
35 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $1,196 · 2021: $2,191 · 2022: $1,965 · 2023: $2,107 · 2024: $2,422 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,892 · Education: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,891.72 |
| Education | $542.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,902.97 | 2019-2025 | |
| Ucb, INC. | $1,746.15 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $1,298.65 | 2021-2025 | |
| Pfizer INC. | $1,283.61 | 2019-2025 | |
| Janssen Biotech, INC. | $1,197.20 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $896.97 | 2019-2025 | |
| Dermavant Sciences, INC. | $433.69 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $422.58 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $382.67 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $282.92 | 2020-2024 | Dupixent |
| Amgen INC. | $279.89 | 2019-2023 | Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $253.67 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $246.08 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $206.31 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $194.48 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $181.29 | 2019-2024 | Aklief, Twyneo, Oracea |
| Dermira, INC. | $179.24 | 2019-2021 | |
| Lilly USA, LLC | $174.72 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $170.32 | 2025 | Vtama |
| Almirall LLC | $151.88 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $139.77 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $122.41 | 2020 | |
| Organogenesis INC. | $51.95 | 2020-2023 | Puraply |
| Mayne Pharma Commercial LLC | $42.31 | 2019-2020 | |
| Biofrontera INC. | $40.30 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $33.16 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.50 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.58 | 2019 | |
| Celgene Corporation | $22.92 | 2019 | |
| Botanix Sb INC | $20.58 | 2025 | Sofdra |
| Genentech USA, INC. | $18.49 | 2019 | |
| Mimedx Group, INC. | $17.48 | 2024 | |
| Taro Pharmaceuticals USA, INC. | $15.30 | 2019 | |
| Encore Dermatology INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lionel Handler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.